NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?
Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.
advertisement
Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Rep. Raul Ruiz on the physician shortage and more
Next article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The cancer drug shortage isn’t new — and neither are the solutions
